Spray-drying: an opportunity for orally inhaled drug products
Orally inhaled drug products offer many therapeutic advantages over other dosage forms, the primary advantage being a direct delivery to the central nervous system. As such, drug developers can produce delivery strategies that reduce the chances of patients experiencing adverse effects.
Successful formulation is reliant on specialised inhalation and characterisation expertise and an in-depth understanding of the variables that can affect product quality.
To this end, there is a growing interest among drug manufacturers and the wider pharmaceutical industry in development techniques for inhaled drug delivery, such as spray drying.
Aditya R. Das, Ph.D., MBA, director of business development at Recipharm, authored an article for Pharmaceutical Manufacturing and Packing Sourcer (PMPS) discussing the advantages of using respirable engineered dry powder for inhalation products. He also explores the 505(b)(2) New Drug Application (NDA) and its suitability as an effective pathway to market.
For the full article see pages 31-35 here: http://edition.pagesuite-professional.co.uk/html5/reader/production/default.aspx?pubname=&pubid=f2590869-3337-4e0f-a382-a8d327f77d40